Industry
Biotechnology
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 7:43 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 3:39 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 2:13 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 10:17 am
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 5:24 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 3:02 pm
Portfolio Pulse from Vandana Singh
June 06, 2024 | 1:52 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.